SEK 2.75
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Newbury Pharmaceuticals AB (publ), a hybrid pharmaceutical enterprise, serves both the Swedish and wider Scandinavian markets. Formed in 2020 and headquartered in Lund, Sweden, the company provides a variety of therapeutic solutions, with a strong emphasis on oncology, rare diseases, and neurology, in addition to other treatment categories.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E.
Data is available to registered users only